Tetrahydroxystilbene glucoside / IL6 Cancer Research Results

TSG, Tetrahydroxystilbene glucoside: Click to Expand ⟱
Features:

Tetrahydroxystilbene glucoside (TSG; 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside) is an isolated stilbene glycoside and a major bioactive constituent of Polygonum multiflorum Thunb. TSG has antioxidant, anti-inflammatory, mitochondrial-protective, neuroprotective and cardiovascular effects in preclinical studies. In Alzheimer-related models, it has reduced amyloid-β toxicity and microglial activation, supported synaptic plasticity, protected against mitochondrial dysfunction and improved learning or memory outcomes. Alternative names include THSG, PM-SG and tetrahydroxystilbene glucoside.



IL6, Interleukin-6: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Interleukin-6 (IL-6) is a cytokine that plays a significant role in inflammation and the immune response. It is produced by various cell types, including T cells, B cells, macrophages, and fibroblasts.
IL-6 can promote tumor cell proliferation and survival. Many cancer cells produce IL-6, which can create an autocrine loop that supports their growth.
IL-6 is a high-value inflammatory biomarker in cancer, reporting cytokine burden, catabolic stress, and STAT3-linked survival signaling. While not tumor-specific, elevated and rising IL-6 strongly predicts poor prognosis and limited treatment tolerance, making it an important system-state indicator alongside CRP and ferritin.


Scientific Papers found: Click to Expand⟱
7045- EMD,  TSG,    Synergic effects and possible mechanism of emodin and stilbene glycosides on colorectal cancer
- vitro+vivo, CRC, NA
Apoptosis↑, TumCMig↓, TumVol↓, IL6↓, TGF-β↓, i-P53↓, i-STAT3↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

i-P53↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

i-STAT3↓, 1,  

Migration(tgid=13) ⓘ

TGF-β↓, 1,   TumCMig↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IL6, Interleukin-6
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:428  Target#:158  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page